Papers/PMID:37159264
Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease.
JCI insight2023The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
coenzyme Q10 — no detected effect on maximal oxygen uptake
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Cardiorespiratory fitness (CRF) and VO2 peak were not significantly different with NR and CoQ10 supplementation, with means of 21.38 ± 4.93 mL/min/kg (P = 0.36) and 21.41 ± 4.74 (P = 0.33), respectively and Table 2).”
Quoted verbatim from Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease.. - Study
- RCT
- Duration
- 6 weeks
- Dose
- 1200 mg/day
- Population
- adults with chronic kidney disease, eGFR under 60 mL/min/1.73m2
Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease.2023PMID:37159264Permalink